Clinical Trial Update: 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa [Phase 2]

View source ↗

Summary

Phase 2 double-blind, placebo-controlled study of istradefylline at 20 and 60 mg/day in Parkinson's disease patients on levodopa/carbidopa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nourianz (istradefylline)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED